Sprache auswählen
CD28
CD28 Molekülinformation
| Englischer Name | T-cell-specific surface glycoprotein CD28 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 32 | Target-Alias | CD28，CD28 Antigen，T-Cell-Specific Surface Glycoprotein CD28，CD28 Antigen (Tp44)，Tp44，CD28 Antigens，CD28 Molecule，T-Cell-Specific Surface Glycoprotein |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | T-cell-specific surface glycoprotein CD28 |
| Target-Alias | CD28，CD28 Antigen，T-Cell-Specific Surface Glycoprotein CD28，CD28 Antigen (Tp44)，Tp44，CD28 Antigens，CD28 Molecule，T-Cell-Specific Surface Glycoprotein |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 32 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
CD28 Produktliste
- Attribut
Protein (9)Antibody (6)Kits (1)
- Produktbibliothek
Online (16)
- Spezies
Mouse (10)Human / Cynomolgus / Rhesus macaque (5)Rat (1)
- Etikett
His Tag (3)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (1)Fc Tag (2)His Tag & Avi Tag (2)- (7)
- Marker
Unconjugated (9)Biotin-labeled (4)- (1)PE Labeled (1)APC Labeled (1)
In den Warenkorb legen
Gesamtmenge16
- 1
- 2
CD28 Molekülhintergrund
T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.
CD28 Molekülalias
CD28,Tp44
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Nezastomig | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| Lulizumab pegol | Lulizumab; BMS-931699 | Phase 2 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Rejection of renal transplantation; Sjogren-Larsson Syndrome | Details |
| Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Autoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders | Details |
| MDX-2003 | MDX-2003 | Phase 2 Clinical | ModeX Therapeutics Inc | Autoimmune Diseases; Leukemia, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Waldenstrom Macroglobulinemia | Details |
| Pegrizeprument | FR-104; JNJ-3133; VEL-101 | Phase 2 Clinical | Effimune | Arthritis, Rheumatoid; Postoperative Complications; Rejection of renal transplantation | Details |
| TC-510 | TC-510 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| REGN-17372 | REGN17372; REGN-17372 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| ZGGS-34 | ZGGS34; ZGGS-34 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| MDX-2001 | MDX2001; MDX-2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Marlotamig | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| REGN-5668 | REGN-5668 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| ATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
| B7-H3.CD28Z.CART therapy (Band Of Parents) | Phase 1 Clinical | The Band Of Parents | Neuroblastoma; Solid tumours | Details | |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| SSS-59 | SSS59; SSS-59 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Neoplasms | Details |
| RNDO-564 | RNDO-564 | Phase 1 Clinical | Rondo Therapeutics | Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| SAR-446422 | SAR446422; SAR-446422 | Phase 1 Clinical | Sanofi | Autoimmune Diseases | Details |
| JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| JNJ-9401 | JNJ-9401 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms | Details |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | Details |
| JNJ-87189401 | JNJ-87189401 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| REGN5837 | REGN5837; REGN-5837 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, Non-Hodgkin | Details |
| CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Scleroderma, Systemic | Details |
| XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Prostatic Neoplasms, Castration-Resistant; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main